

Date: 14.02.2018

The Secretary,
 BSE Limited
 Phiroze Jeejeebhoy Towers
 Dalal Street, MUMBAI 400 001

2. The Secretary, National Stock Exchange of India Ltd Exchange Plaza, 5th Floor Plot No. C/1, G Block Bandra-Kurla Complex Bandra (E), MUMBAI 400 051

Company Code: 537291

Sub: Submission of information under regulation 33 (3) (a) of the SEBI (LODR) Regulations, 2015.

Dear Sir,

Please find enclosed herewith Quarterly unaudited Financial Results for the quarter ended 31st December 2017.

The above information is being provided to you under Regulation 33 (3) (a) of The SEBI (LODR) Regulations, 2015.

This is for your information and record purpose.

Thanking You.

Yours Faithfully, For Nath Bio Genes (India) Limited

Authorized Signatory

Nath House, Nath Road, Aurangabad - 431005 (MS) Tel: 0240-2376314/5/6/7
 Email: info@nathseeds.com www.nathbiogenes.com

■ 1, Chateau Windsor, 86 Veer Nariman Road, Mumbai - 400020 (MS) Tel: 022-22871001, 22875653/4/5





Mach Bio-Genes (I) Ltd.

ANDALONE UNAUDITED RESULTS FOR THE QUARTER AND 9 MONTHS ENDED 31/12/2017

100							Rs in Lacs
	Particulary	Quarter Ended			Nine Months Ended		Year Ended
No.		31/12/2017 Unaudited	30/09/2017 Unaudited	31/12/2016. Unaudited	31/12/2017 Unaudited	31/12/2016 Unaudited	31/03/2017 Audited
-	ncome			1017.00	14163.89	11895.58	16972.56
	(a) Revenue from operations	2575,10	1439.14	1817.29		36.04	65.91
	(b) Other Operating Income	3.00	4,53	9.93	12.97	39.04	00,43
	Total Income	2578.19	1443.67	1826.22	14176.86	11931.62	17038.47
	Expenses						F0.45.08
	a) Cost of Material Consumed	2459.03	289.11	2201.58	4318.02	5593.82	5845.98
	b) Purchase of Stock-in-Trade	144.35	0.00	0.00	162.79	0.00	196.52
-1	c) Changes in Inventory of Finished Goods						
	& Work in Progress	(1808.69)	(3.26)	(1609.31)	1949.49	(631.71)	1040.42
		407.83	382.62	334.01	1174.09	1165.73	1373.61
	d) Employee Benefit Expense	272 82	267.32	264.75	825.54	674.34	965.71
	e) Finance Costs	25.00	25.00	87.97	75.00	263.31	303.04
	f) Depreciation & Amortisation Expenses	424.28	72.95	235.62	2255.42	2540.22	3903.67
	g) Selling & Distribution Expenses	259.01	49.68	134.34	630.00	419.25	1727.25
	h) Other Expenditure	200.01	-			40004.00	15356.19
	Total Expenses	2183.64	1083.43	1648.96	11390.36	10024.96	1682.28
111	Profit before Exceptional items & Tax (I - II)	394.56	360.25	177.26	2786.51	1906.66	6.9
157	Exceptional Items Income/(Expenses)	0.00	0.00	0.00	(13.86)	0.08	
101	Profit Before Tax (III+IV)	394.56	360.25	177.26	2800.37	1906.58	1675.34
VI	Tax Expense	244		60.00	32 67	60.00	47.10
-	(a) Current Tax	0.00	4.62	A TO TO TO TO A	0.00	0.00	0.0
	(b) Deferred Tax	0.00	0.00	0.00			1628.2
VII	Net Profit for the period (V-VI)	394.56	355.63	117.26	2767.70	1846.58	1020.2
7111	Other Comprehensive Income						
	1. (a) Items that will not be reclassified to			0.00	0.00	0.00	0.0
	Profit or Loss	0.00	0.00	0.00	0.00	0.00	5,0
	(b) income tax relating to items that will not			0.00	0.00	0.00	0.0
	be reclassified to Profit or Loss	0.00	0.00	2777		0.00	0.0
	Loss	0.00	0.00	0.00	0.00	0.00	.0.0
	(b) Income tax rolating to items that will be			0.00	0.00	0.00	0.0
	reclassified to Profit or Loss	0.00	0.00	0.00		0.00	-0.0
	Total other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.0
IX	Total Comprehensive Income for the period (VII + VIII)	394.56	355.63	117.26	2767.70	1846.58	1628.2
	Paid Up Equity Share Capital					100000	****
	(Face Value Rs. 10/- each)	1600.40	1600.40	1600.40	1600.40	1600.40	1600.4
X	Reserves (excluding Revaluation	THE PARTY OF THE P					
XI	Reserves (excluding Revaluation Reserves) as per balance sheet of previous	44005.04	14531.38	12376.58	14925.94	12376.58	12158.2
	The state of the s	14925.94	14551.36	12010.00	171 2010 1077	1001,000	
XII	Earning per share (of Rs 10/- each) (not annualised)	2.47	2.22	0.73	17.29	11.54	10:1

Date: 14th February 2018

(1) Above financial results are taken on record by the Board of Directors in their meeting held on 14th February 2018.
(2) The company is constantly improving its Product Mix for better profits and launching new research products in various crops.

(2) The company is constantly improving its Product Mix for better profits and launching new
(3) The company is dealing in one major product segment, i.e. Seed Cuttivation
(4) The Company has commenced accounting as per IAS from 1 Apr 2017.

(5) Investor complaints - Opening Balance - 0, Received and Solved - 1, Closing Balance - 0.

FOR NATH BIO-GENES (INDIA) LTD

* Nath B

MANAGING DIRECTOR DIN 00119601

ASHOK R. MAJETHIA & CO. Chartered Accountants

R. MAJETHIA PROPRIETOR MEMBERSHIP NO. 124781 OKR. MAJ CHARTERED ACCOUNTANT M.NO.124781 THOPC

ASHOK R. MAJETHIA

BCom. F.C.A CHARTERED ACCOUNTANT Ashok R. Majethia & Co. Chartered Accountants Utsav Complex, Office No. 7, Bazar Peth, Dist. Raigad, Khopoli – 410 203

Tel:- (02192) 269908

Mobile: - 9404711539 / 9372169952 Email: - ashokmajethia@redifmail.com

LIMITED REVIEW REPORT

To The Board of Directors of Nath Bio-Genes (India) Limited

1. We have reviewed the accompanying statement of unaudited financial results for the quarter ended 31st December, 2017 (the Statement) of NATH BIO-GENES (INDIA) LIMITED (the Company). This statement has been prepared by the Company pursuant to regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 (the "Listing Regulation, 2015" read with SEBI circular dated July 05, 2016 which has been initialed by us for identification purposes.

The statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Further, the management is also responsible to ensure that Company's Accounting Policies used in preparation of this statement are consistent with those used in the preparation of companies opening unaudited balance Sheet as at 1st April 2017 prepared in accountance with Companies (Ind-AS) Rules 2015 prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies. Our responsibility is to issue a report on the statements based on our review.

2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement.



- 3. A review is limited primarily to enquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement has not been prepared in all material respect in accordance with Ind-AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of regulation 33 of the Listing Regulations, 2015 read with SEBI Circular dated 5th July 2015 including the manner in which it is to be disclosed, or that it contains any material mis-statement.

MOPO

For Ashok R Majethia

Chartered Accountants

FRN: 127769W

Ashok Majethia

Proprietor M No: 124781

Place: Aurangabad Date: 14.02.2018